This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Sorry! 

It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later - or visit our Novo Nordisk Science Hub congress overview in the meantime.

Welcome and introduction

Treatment individualisation in haemophilia A

The role of factor VIII in current treatment landscape: Real world data on patient experience

What does more ambitious prophylaxis mean for your patients with haemophilia B?

Panel discussion & Meeting closure

Speaker - Chantal Mathieu

Johnny Mahlangu, BSc, MBBCH, Mmed, FCPath

Professor of Haematology at the University of Witwatersrand, Johannesburg, South Africa


Johnny Mahlangu is a Professor of Haematology in the Faculty of Health Sciences of the University of the Witwatersrand and the National Health Laboratory Service and a Consultant Clinical Haematologist in Charge of Haematology at the Charlotte Maxeke Johannesburg Academic Hospital. Prof Mahlangu received his undergraduate and postgraduate training in science and medicine at the University of the Witwatersrand with haematology specialist and clinical haematology sub-specialist qualifications through the Colleges of Medicine of South Africa. His main area of research is novel therapies in bleeding disorders in which he has served as Principal Investigator for many international multicentre studies. He has published many peer review journal articles and presented many oral talks and posters at national and international scientific meetings.

 

Prof Mahlangu is currently the President of the College of Pathologists in South Africa and Chairman of the South African Medical Research Council Board. He is a recipient of many awards, the most recent include the Wits University Vice-Chancellor Academic citizenship award in 2018, the American Society of Haematology Global Capacity Building award in 2019, the Publons top 1% cross-field reviewer award in 2019, Wits University Vice-Chancellor Research award in 2020 and an elected member of the Academy of Science of South Africa in 2020, the International Society on Thrombosis and Haemostasis Esteemed Career award in 2021.


Read full bio